Yabao and UniSA collaborate on drug discovery laboratory
Chinese pharmaceutical company Yabao Pharmaceutical and the University of South Australia (UniSA) will collaborate on the development of new cancer treatments through a co-funded drug discovery laboratory, to be led by UniSA Professor Shudong Wang.
Yabao Pharmaceutical will provide cash and in-kind contributions towards drug discovery and development at the laboratory, with potential candidates to be identified by UniSA. Yabao will have exclusive rights to develop and commercialise the drug candidates in China, while UniSA will retain rights in all other markets.
“We are thrilled to have the opportunity to work with the University of South Australia’s highly regarded scientists and laboratories to jointly find a way to develop important new treatments for cancer patients,” said Dr Peng Wang, president of R&D at Yabao Pharmaceutical, who noted that Yabao is constantly seeking to build relationships with organisations whose programs complement the company’s development and commercial capabilities.
Professor Wang, who is the head of UniSA’s Centre for Drug Discovery and Development, said she is looking forward to a productive collaboration with Yabao.
“The financial resources resulting from this agreement will help to rapidly advance our drug discovery towards clinical development — a goal we all share,” Professor Wang said.
Abnormal brain protein targeted in Parkinson's study
Researchers have identified a new brain protein involved in the development of Parkinson's...
Epilepsy disease model treated in a laboratory dish
A research team has used an epilepsy-like disease model in a laboratory dish to demonstrate that...
Newborns have elevated levels of an Alzheimer's biomarker
What do the brains of newborns and patients with Alzheimer's disease have in common? Both...
